Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model | Zendy

Lindsay M. Avery | Zendy; Kamilia Abdelraouf | Zendy; David P. Nicolau | Zendy

Open Access

Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model

Author(s) -

Lindsay M. Avery,

Kamilia Abdelraouf,

David P. Nicolau

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00948-18

Subject(s) - cefepime , acinetobacter baumannii , medicine , in vivo , acinetobacter , microbiology and biotechnology , imipenem , biology , antibiotics , pseudomonas aeruginosa , bacteria , antibiotic resistance , genetics

We evaluated thein vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) against cefepime-resistantAcinetobacter baumannii strains (n = 13) in the neutropenic murine lung infection model. Twelve isolates were meropenem resistant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research